ARUP offers nucleic acid amplification (NAA) testing for the diagnosis of current COVID-19 infection and two immunoglobulin G (IgG) antibody tests (targeting spike and nucleocapsid proteins, respectively) to evaluate individuals for exposure to SARS-CoV-2.
Diagnostic Tests
SARS-CoV-2 (COVID-19) by NAA (3002638)
Clinical Use:
Recommended molecular testing (NAA) for the detection of SARS-CoV-2 for symptomatic patients. Because symptoms for COVID-19 are similar to those of other respiratory infections, a clinical diagnosis alone is not sufficient to make a COVID-19 diagnosis.
Benefits:
- We offer a rapid turnaround time.
- ARUP’s molecular assays are designed to detect several SARS-CoV-2 RNA gene targets, allowing for the detection of COVID-19 variants.
- We accept multiple specimen types, including nasopharyngeal swab, oropharyngeal swab, nasal swab, or saliva specimens.
Antibody Tests
COVID-19 IgG, Qualitative by CIA (3002776)
Clinical Use:
Use for the qualitative detection of IgG antibodies against the nucleocapsid protein of SARS-CoV-2 that develop in response to natural infection with SARS-CoV-2 (COVID-19 infection). These antibodies do not develop as a result of a COVID-19 vaccination.
COVID-19 IgG (Spike), Semi-Quantitative by CIA (3003648)
Clinical Use:
Use for the detection of IgG antibodies against the spike protein (S1) of SARS-CoV-2 that develop in response to natural infection with SARS-CoV-2 or from a COVID-19 vaccination.
Benefits:
- We offer a rapid turnaround time.
- Our highly sensitive and specific assays detect low levels of IgG antibodies.
Related Testing
Vaccine-Induced Immune Thrombotic Thrombocytopenia
Unusual thrombotic events with thrombocytopenia have been reported in a small number of patients following receipt of two SARS-CoV-2 vaccines (AstraZeneca and Johnson and Johnson/Janssen). For more information, please refer to the Quick Answers for Clinicians section of the Heparin Induced Thrombocytopenia - HIT ARUP Consult topic.
Clinical Resources
Testing Guidance
- IDSA Guidelines on the Diagnosis of COVID-19: Molecular Diagnostic Testing. Updated Sep 2023; accessed May 2024.
- Recommendations for molecular diagnostic tests
- IDSA Guidelines on the Diagnosis of COVID-19: Serologic Testing. Published Feb 2024; accessed May 2024.
- Recommendations for serology tests
- CDC COVID-19 Testing Overview. Updated Mar 2024; accessed May 2024.
- Recommendations for viral and antibody testing
- CDC COVID-19 Antibody Testing. Published Dec 2022; accessed May 2024.
- Interim Guidelines for COVID-19 Antibody Testing in Clinical and Public Health Settings
ARUP’s COVID-19 assays are offered under FDA Emergency Use Authorization (EUA). Please visit the FDA web page, EUA Authorized Serology Test Performance, for more information.
Decision Support: ARUP Consult®
ARUP provides ARUP Consult as a resource to hospital and laboratory clients, healthcare providers, and patients at no cost.
- COVID-19 - SARS-CoV-2 topic